Patients with adenocarcinoma and MMR determination were reclassified using only the evaluation of PMS2 and MSH6. The diagnostic performance of the 2-antibody test (proposed panel) and 4-antibody ...
A discovery dataset of 99 variants with unequivocal results of RNA in vitro studies, located in the 10 exonic and 20 intronic nucleotides adjacent to exon–intron boundaries of BRCA1, BRCA2, MLH1, MSH2 ...
Immunohistochemical analysis revealed positivity for CDX2, SATB2, CK7, CK20, PMS2, MLH1, MSH2, MSH6, and wild-type p53, while showing negativity for p16, Pax-8, ER, PR, Muc-6, Muc-5AC and claudin 18.2 ...
Impact of Insurance Status on Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma This retrospective analysis included patients with cancer who had commercial ctDNA tests (K-Track, Gene ...
Assessing Clinical Value of New Treatment Strategies: ESMO-MCBS and ASCO-VF Evaluation in Phase III Trials at ASCO Annual Meeting 2022 Demand for germline hereditary cancer genetic testing has ...
Living cells respond to DNA damage by a variety of mechanisms, including a series of biochemical pathways called DNA repair. These include three discrete pathways for the excision of damaged bases ...
1 Division of Gynecologic Oncology, University of Colorado Hospital, Aurora, CO, USA 2 Division of Gynecologic Oncology, University of Minnesota, Minneapolis, MO, USA 3 Division of Gynecologic ...
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be ...
aDepartment of Medicine, University of Verona, School of Medicine and University Hospital Trust of Verona (AOUI Verona), Verona 37134, Italy bDepartment of Diagnostics and Public Health, and ARC-Net ...
1Department of Histopathology and Morbid Anatomy, Trinity Translational Medicine Institute, Trinity College Dublin, Dublin, Ireland. 2Department of Medical Oncology, St. James’s Hospital, Dublin, ...